Dr. Chaudhry on DRd Triplet in Transplant-Ineligible Multiple Myeloma

Maria Chaudhry, MBBS, a hematologist at The Ohio State University Comprehensive Cancer Center—James, discusses the use of daratumumab (Darzalex), lenalidomide (Revlimid), and dexamethasone (DRd) in transplant-ineligible patients with multiple myeloma.

In the phase III MAIA trial, transplant-ineligible patients were randomized to receive DRd or the combination of lenalidomide and dexamethasone alone until progression. Approximately 44% of patients were 75 years of age or older.

The addition of daratumumab resulted in a 44% reduction in the risk of progression or death versus the combination alone, says Chaudhry. Moreover, the overall response rate (ORR) with daratumumab was also better, at 93%. Data from the trial served as the basis for the regimen’s approval in June 2019.

In terms of adverse events, the incidence of grade ≥3 neutropenia was higher in the daratumumab arm, concludes Chaudhry.